These findings demonstrate that treatment with a hunger-inducing ghrelin agonist is sufficient to reduce AD-related cognitive deficits and pathology in Tg AD model mice, similar to the effect of CR on the development of AD pathology. Here, GHRL is linked to Cognitive impairment.